Last reviewed · How we verify
TLC-6740 Oral Solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TLC-6740 Oral Solution (TLC-6740 Oral Solution) — OrsoBio, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TLC-6740 Oral Solution TARGET | TLC-6740 Oral Solution | OrsoBio, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TLC-6740 Oral Solution CI watch — RSS
- TLC-6740 Oral Solution CI watch — Atom
- TLC-6740 Oral Solution CI watch — JSON
- TLC-6740 Oral Solution alone — RSS
Cite this brief
Drug Landscape (2026). TLC-6740 Oral Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/tlc-6740-oral-solution. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing